Login
$ELAN
$25.85 -$0.56 (2.12%) Pre-market

$ELAN 8-K SEC Filings

Filed On Filing
06 Nov 2026 8-K: Results of Operations and Financial Condition

Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected]

05 Aug 2026 8-K: Results of Operations and Financial Condition

Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected]

27 May 2026 8-K: Submission of Matters to a Vote of Security Holders

Elanco Animal Health Incorporated (the “Company”) held its annual meeting of shareholders on May 21, 2026. Voting results for each matter submitted to a vote at the 2026 annual meeting are provided below.

06 May 2026 8-K: Results of Operations and Financial Condition

Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected]

24 Feb 2026 8-K: Results of Operations and Financial Condition

Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected]

12 Jan 2026 8-K: Regulation FD Disclosure

J.P. Morgan Healthcare Conference Jeff Simmons President & CEO January 13, 2026

09 Dec 2025 8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure

Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]

05 Nov 2025 8-K: Results of Operations and Financial Condition

Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected]

03 Nov 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

THIS AMENDMENT NO. 3 TO CREDIT AGREEMENT (this “Agreement”), dated as of October 31, 2025, is entered into among ELANCO ANIMAL HEALTH INCORPORATED, a corporation formed under the laws of Indiana (the “U.S. Borrower” or the “Borrower Repr...

07 Aug 2025 8-K: Results of Operations and Financial Condition

Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected]

26 Jun 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

This FIRST AMENDMENT TO RECEIVABLES LOAN AGREEMENT, dated as of June 25, 2025 (this “Amendment”), is entered into by and among Elanco Spear LLC, a Delaware limited liability company, as borrower (the “Borrower”), Elanco US Inc. (“Elanco”...

28 May 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]

21 May 2025 8-K: Submission of Matters to a Vote of Security Holders

Elanco Animal Health Incorporated (the “Company”) held its annual meeting of shareholders on May 16, 2025. Voting results for each matter submitted to a vote at the 2025 annual meeting are provided below.

07 May 2025 8-K: Results of Operations and Financial Condition

Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected]

17 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]

25 Feb 2025 8-K: Results of Operations and Financial Condition

Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected]

13 Jan 2025 8-K: Regulation FD Disclosure

J.P. Morgan Healthcare Conference January 14, 2025 Jeff Simmons President & Chief Executive Officer

12 Nov 2024 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Investor Contact: Kathryn Grissom, +1.317.273.9284, [email protected]

07 Nov 2024 8-K: Results of Operations and Financial Condition

Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected]

16 Oct 2024 8-K: Regulation FD Disclosure

On October 15, 2024, representatives of Elanco Animal Health Incorporated (the “Company”) presented the abstract titled “Serologic response to core booster vaccinations in dogs treated with a novel JAK inhibitor” at the International Soc...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support